Comparative Pharmacology
Head-to-head clinical analysis: ISRADIPINE versus TIAZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISRADIPINE versus TIAZAC.
ISRADIPINE vs TIAZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
Oral: 120-360 mg once daily; maximum 540 mg daily.
None Documented
None Documented
Clinical Note
moderateIsradipine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid."
Clinical Note
moderateIsradipine + Furosemide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide."
Clinical Note
moderateIsradipine + Bumetanide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide."
Clinical Note
moderateIsradipine + Travoprost
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker
"Isradipine may increase the hypotensive activities of Travoprost."